Outlook52High Tide · stable · Bottom 50% of universe (3991)
Squeeze Score
27
Idle ·
Days to cover6.13
Short interest3.92% of float
Borrow rate30.46%
Short interest trend-0.18% (30d)
Trend
Bullish
Trending up — 3 of 8 indicators bullish
Recent Smart Money
0 buys
Quiet · $0 · 14d · 3 super investors
Key statistics
Market Cap
$32.63B
52-week range
$135.67 – $224.51
63% from low
Day range
$220 – $224
Open $221.15
Volume
465k
vs 871k avg · 53%
P/E (TTM)
39.5
Fwd 13.6
Earnings
Oct 29
50d · est $2.31
Country ranks
US Rank— Country rank populator pending
BW universe: US & CA common stocks only · ETFs and mutual funds excluded · Methodology →
Price chart with forecast cone and smart-money events
Wall Street Analyst Consensus
Wall Street Analyst Consensus
Aggregate of 26 third-party analyst opinions — not Quantellect advice.
12-mo median price target
$241
26 Wall St 12-month targets
High
$300
Average
$236
Low
$150
Recent price history, then Wall-Street analysts’ 12-month price targets (high / median / low) shown forward to the 12-month target levels. Targets are third-party analysts’ estimates of future performance — not guarantees, and not Quantellect recommendations. Past results do not guarantee future returns.
Per-analyst ratings are not yet available for this ticker.
Aggregate of third-party analysts’ published opinions, shown for information only — not Quantellect advice. The 64/100 Analyst Score (Buy) is Quantellect’ documented weighting of the rating distribution on the same 0–100 scale as the Tide / Squeeze / Trend / Money scores; the verdict label is derived from that score. Past results do not guarantee future returns. Source: aes.
Not investment advice. Past results do not guarantee future returns. Scores, narratives, and historical-cohort statistics on this page are generated by Quantellect algorithms from public filings, market data, and AI synthesis, and describe the historical performance of structurally similar setups in our universe; failures are included. Data may be 15-minute delayed, contain errors, or be revised. Always do your own research and consult a licensed financial advisor before making investment decisions.
BW analyst · the story · Today
Today story being generated
The BW analyst hasn't produced a story for this ticker yet — both
today and outlook clocks are pending. Check back shortly; the Phase
3 LLM pipeline refreshes both clocks on a rolling cadence.
Not investment advice. Generated with AI from Quantellect data layers. May contain errors. Review the cited sources and conduct your own research.
Price, smart-money events, and how similar setups behaved in the past
Social pulseBootstrap · early daysStocktwits · 24h
1
Mentions · ↑ 0% vs avg
Sentiment0.00 net
Top voice— · 0
Spike triggerBelow 30d avg
News & PR7d · 4 articles
0.00
Net article tone (-1 to +1)
Latest PRStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Top storyStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Risk storyStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
